Oppenheimer & Co’s Verastem VSTM Stock Holding History

Oppenheimer & Co’s Portfolio VSTM Stock Details VSTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-888	Closed	-$33K	–	1399
2017 Q4	$33K	Buy	888 +45	+5%	+$2.03K	﹤0.01%	1300
2017 Q3	$48K	Sell	843 -9	-1%	-$425	﹤0.01%	1271
2017 Q2	$23K	Buy	+852	New	+$21.7K	﹤0.01%	1286
2013 Q3	–	Sell	-1,619	Closed	-$270K	–	1372
2013 Q2	$270K	Buy	+1,619	New	+$195K	0.01%	971

Other funds holding VSTM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Oppenheimer & Co's VSTM Position: Q1 2018 in Review

Oppenheimer & Co sold out of Verastem (VSTM) in Q1 2018, closing a stake of 888 shares — an estimated $33K sold.

Oppenheimer & Co first reported a position in VSTM in Q2 2013 and held it in 4 quarters. The position peaked at $270K in Q2 2013. 78 funds tracked by Wall St. Rank hold VSTM as of Q1 2018.

Oppenheimer & Co reported no remaining Verastem position as of Q1 2018 after selling out during the quarter.
Oppenheimer & Co sold 888 Verastem shares in Q1 2018, an estimated $33K.
Oppenheimer & Co first reported a position in Verastem in Q2 2013 and held it in 4 quarters.
Oppenheimer & Co's Verastem position peaked at $270K in Q2 2013.
78 funds tracked by Wall St. Rank held Verastem as of Q1 2018.

Based on Oppenheimer & Co's 13F filing for Q1 2018, filed 1 May 2018.